经肝动脉90Y-DOTATOC肽受体放射性核素治疗神经内分泌肿瘤肝转移
前瞻性单中心开放标签先导研究纳入肝转移为主的神经内分泌肿瘤初治患者,经肝固有动脉给予3.5±0.2 GBq 90Y-DOTATOC,主要观察疗效与毒性。因缺乏疗效在计划分析前10例后终止,3个月时90%患者稳定、10%进展,无部分或完全缓解;肝转移瘤动脉给药SUVmax未高于静脉给药,中位动脉/静脉SUVmax比值为0.81。
要点
- 经肝动脉90Y-DOTATOC单次治疗未使肝转移瘤缩小,3个月时90%稳定、10%进展。
- 肝转移瘤动脉给药SUVmax未高于静脉给药,中位动脉/静脉SUVmax比值0.81。
- 肝肿瘤负荷最高的2例患者在治疗后6个月内死亡,治疗被认为是可能因素。
核心结论
- 经肝固有动脉给予PRRT未重现既往报道的肝肿瘤摄取增高。
- 单次90Y-DOTATOC治疗未诱导肿瘤缩小,提示可能需要更多治疗周期。
- 高肝肿瘤负荷患者可能存在安全性顾虑,应据此指导未来研究的患者选择。
研究设计与样本
- 前瞻性单中心开放标签先导研究,纳入肝转移为主的PRRT初治成人神经内分泌肿瘤患者。
- 患者先行静脉68Ga-DOTATOC基线PET/CT,再经肝固有动脉30分钟内给予3.5±0.2 GBq(94.7±5.4 mCi)90Y-DOTATOC。
- 前5例患者另接受动脉68Ga-DOTATOC并行PET/CT。
- 所有患者随访疗效(RECIST 1.1版)和毒性(不良事件通用术语标准4.0版)至少6个月,可选随访至1年。
- 研究在计划分析前10例患者后因缺乏疗效而终止。
主要发现
- 3个月时最佳疗效为稳定病90%(9/10例)、进展10%(1/10例);6个月时稳定病8/10例、进展2/10例。
- 另有1例患者在6个月随访期后但在可选1年随访期内出现进展,未观察到部分缓解或完全缓解。
- 肝肿瘤负荷最高的2例患者在治疗后6个月内死亡,治疗被认为是可能因素。
- 动脉给药患者肝转移瘤摄取未高于静脉给药患者,病灶水平中位动脉/静脉SUVmax比值为0.81(范围0.36-2.09)。
关键数值与推荐
- 疗效评价采用RECIST 1.1版,毒性评价采用不良事件通用术语标准4.0版。
- 90Y-DOTATOC经肝固有动脉给药剂量为3.5±0.2 GBq(94.7±5.4 mCi),输注30分钟。
- 3个月时稳定病90%(9/10例)、进展10%(1/10例);6个月时稳定病8/10例、进展2/10例。
- 病灶水平中位动脉/静脉SUVmax比值为0.81(范围0.36-2.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为前瞻性单中心开放标签先导研究,在计划分析前10例患者后因缺乏疗效而终止。
- 单次90Y-DOTATOC治疗未诱导肿瘤缩小,作者认为可能需要更多治疗周期。
- 高肝肿瘤负荷患者可能存在安全性顾虑,作者认为应据此指导未来研究的患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the high frequency of liver metastases in neuroendocrine tumor patients, we aimed to determine whether hepatic intraarterial administration of 90Y-DOTATOC peptide receptor radionuclide therapy (PRRT) would increase treatment efficacy while reducing systemic toxicity compared with systemic toxicity from intravenous administration as previously reported in the literature. Methods: PRRT-naïve adult neuroendocrine tumor patients with liver-dominant metastases were enrolled in a prospective single-center, open-label pilot study. The patients underwent baseline PET/CT using intravenous 68Ga-DOTATOC. Then, 3.5 ± 0.2 GBq (94.7 ± 5.4 mCi) of 90Y-DOTATOC were administered into the proper hepatic artery over 30 min. The first 5 patients also received intraarterial 68Ga-DOTATOC and underwent PET/CT. All patients were followed for response (RECIST, version 1.1) (primary aim 2, safety) and toxicity (Common Terminology Criteria for Adverse Events, version 4.0) (primary aim 1, efficacy) for at least 6 mo, with optional follow-up for up to 1 y. In the subset of 5 patients who underwent both intravenous and intraarterial 68Ga-DOTATOC PET/CT, tumor SUVmax was compared between intravenous and intraarterial administration for hepatic tumors, intrahepatic tumors, and uninvolved background organs (secondary aim, intravenous vs. intraarterial uptake). Results: The study was terminated after a planned analysis of the first 10 patients because of lack of efficacy. The best response was stable disease in 90% (9/10 patients) and progressive disease in 10% (1/10 patients) at 3 mo, and stable disease in 8 of 10 patients and progressive disease in 2 of 10 patients at 6 mo. One additional patient developed progressive disease after the 6-mo follow-up period but within the optional 1-y follow-up period. No partial response or complete response was observed. The 2 patients with the highest liver tumor burden died within 6 mo of treatment, with treatment considered a possible contributor. Patients who received intraarterial administration failed to demonstrate higher uptake by hepatic metastases than patients who received intravenous administration, with a median intraarterial-to-intravenous SUVmax ratio of 0.81 (range, 0.36-2.09) on a lesion level. Conclusion: Our study found that administration of PRRT via the proper hepatic artery did not reproduce the increase in hepatic tumor uptake that was previously reported. In addition, the single treatment using 90Y-DOTATOC did not induce tumor shrinkage, indicating that more treatment cycles may be required. Possible safety concerns in patients with a high liver tumor burden should inform patient selection for future studies.
引用
- Lawhn-Heath C, Fidelman N, Chee B, et al. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. J Nucl Med. 2020. PMID: 32513903. doi:10.2967/jnumed.119.241273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。